Danshensu attenuates scopolamine and amyloid-β-induced cognitive impairments through the activation of PKA-CREB signaling in mice

Neurochem Int. 2019 Dec:131:104537. doi: 10.1016/j.neuint.2019.104537. Epub 2019 Aug 16.

Abstract

Alzheimer's disease (AD) is an important chronic neurodegenerative disorder and is mainly associated with cognitive dysfunction. At present, bioactive compounds from traditional medicinal plants have received much attention for the enhancement of cognitive function. Danshensu, a phenolic acid isolated from herbal medicines, has various pharmacological activities in the central nervous system, including anxiolytic-like and neuroprotective properties. The present study aimed to investigate the ameliorating effects of danshensu on scopolamine- and amyloid-β (Aβ) protein-induced cognitive impairments in mice. Danshensu (3 and 10 mg/kg, p.o.) effectively ameliorated scopolamine-induced cognitive dysfunction in mice, as measured in passive avoidance and Y-maze tasks. In a mechanistic study, danshensu inhibited monoamine oxidase A (MAO-A) activity but not MAO-B. Additionally, danshensu treatment increased the dopamine level and the phosphorylation levels of protein kinase A (PKA) and cAMP response element binding protein (CREB), in the cortex of the brain. Furthermore, the ameliorating effect of danshensu against scopolamine-induced cognitive impairment was fully blocked by H89, a PKA inhibitor. Finally, danshensu also ameliorated Aβ-induced cognitive impairments in an animal model of AD. The results revealed that danshensu treatment significantly improved scopolamine and Aβ-induced cognitive impairments in mice by facilitation of dopamine signaling cascade such as PKA and CREB due to MAO-A inhibition. Thus, danshensu could be used as a promising therapeutic agent for preventing and treating AD.

Keywords: Alzheimer's disease; Amyloid-β; Cognitive impairment; Danshensu; Monoamine oxidase; Protein kinase A.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amyloid beta-Peptides / antagonists & inhibitors*
  • Amyloid beta-Peptides / toxicity*
  • Animals
  • Avoidance Learning / drug effects
  • Cognitive Dysfunction / chemically induced*
  • Cognitive Dysfunction / pathology
  • Cyclic AMP Response Element-Binding Protein*
  • Cyclic AMP-Dependent Protein Kinases*
  • Dopamine / physiology
  • Drugs, Chinese Herbal / pharmacology*
  • Isoquinolines / pharmacology
  • Lactates / antagonists & inhibitors
  • Lactates / pharmacology*
  • Male
  • Maze Learning / drug effects
  • Mice
  • Mice, Inbred ICR
  • Monoamine Oxidase Inhibitors / pharmacology
  • Muscarinic Antagonists / toxicity*
  • Phosphorylation / drug effects
  • Scopolamine / antagonists & inhibitors*
  • Scopolamine / toxicity*
  • Signal Transduction / drug effects*
  • Sulfonamides / pharmacology
  • Synaptic Transmission / drug effects

Substances

  • Amyloid beta-Peptides
  • Cyclic AMP Response Element-Binding Protein
  • Drugs, Chinese Herbal
  • Isoquinolines
  • Lactates
  • Monoamine Oxidase Inhibitors
  • Muscarinic Antagonists
  • Sulfonamides
  • 3,4-dihydroxyphenyllactic acid
  • Scopolamine
  • Cyclic AMP-Dependent Protein Kinases
  • N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide
  • Dopamine